SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Sandborn WJ FB, Hanauer SB, Lochs H, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology. 2002; 122: 512530.
  • 2
    Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976; 70: 439444.
  • 3
    Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterology. 1979; 77: 843846.
  • 4
    Campieri M, Ferguson A, Doe W, et al. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Gut. 1997; 41: 209214.
  • 5
    Ferguson A, Campieri M, Doe W, et al. Oral budesonide as maintenance therapy in Crohn's disease—results of a 12-month study. Global Budesonide Study Group. Aliment Pharmacol Ther. 1998; 12: 175183.
  • 6
    Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. Gastroenterology. 1996; 110: 4551.
  • 7
    Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med. 1994; 331: 836841.
  • 8
    Hanauer S, Sandborn WJ, Persson A, et al. Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial. Aliment Pharmacol Ther. 2005; 21: 363371.
  • 9
    Lofberg R, Rutgeerts P, Malchow H, et al. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study. Gut. 1996; 39: 8286.
  • 10
    Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med. 1994; 331: 842845.
  • 11
    Thomsen CA, Jewell D, Wright JP, et al. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. N Engl J Med. 1998; 339: 370374.
  • 12
    Tremaine WJ, Hanauer SB, Katz S, et al. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States. Am J Gastroenterol. 2002; 97: 17481754.
    Direct Link:
  • 13
    Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology. 1994; 106: 287296.
  • 14
    Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology. 1989; 96: 804810.
  • 15
    Mitchell A, Guyatt G, Singer J, et al. Quality of life in patients with inflammatory bowel disease. J Clin Gastroenterol. 1988; 10: 306310.
  • 16
    Irvine EJ. Development and subsequent refinement of the inflammatory bowel disease questionnaire: a quality-of-life instrument for adult patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1999; 28: S2327.
  • 17
    European Medicines Agency Committee for Medicinal Products for Human Use. Guidelines on the development of new medicinal products for the treatment of Crohn's disease. Available at: http://www.emea.europa.eu/pdfs/human/ewp/228499.pdf. 2007
  • 18
    Fredd S. Standards for approval of new drugs for IBD. Inflamm Bowel Dis. 2005; 1: 284294.
    Direct Link:
  • 19
    Deyo RA, Diehr P, Patrick DL. Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation. Control Clin Trials. 1991; 12: 142S158S.
  • 20
    Litcher-Kelly L, Kellerman Q, Hanauer SB, et al. Feasibility and utility of an electronic diary to assess self-report symptoms in patients with inflammatory bowel disease. Ann Behav Med. 2007; 33: 207212.
  • 21
    Sandler RS, Jordan MC, Kupper LL. Development of a Crohn's index for survey research. J Clin Epidemiol. 1988; 41: 451458.